BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 21

Minimed Group Inc

MMEDNASDAQ
Trade with Public
Trade with Public
$21.79
-0.24-1.09%
가까이에: Sep 18, 5:00 PM EST
$21.79
N/A
시간외: Sep 18, 4:01 PM EST
개요뉴스실적 전망이벤트목표가재무심리비교옵션주식 보고서

Minimed Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Minimed Group (MMED).

Price Target Range — 3 Quarters

Analyst Consensus — 12 Analysts

11Buy
1Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$25Upside to Avg. PT+13.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 3, 2026Morgan StanleyKallum TitchmarshPT RaiseOverweight$19→$21
Sep 2, 2026CitigroupJoanne WuenschPT RaiseBuy$23→$26
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26

Citigroup analyst Joanne Wuensch maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $23 to $26.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27

Evercore ISI Group analyst Daniel Markowitz maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $20 to $27.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26

Wells Fargo analyst Larry Biegelsen maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $22 to $26.
Benzinga Newsdesk

These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

MiniMed Group beat Q1 sales estimates with 16.6% growth to $843M; shares rose 7.1% as analysts raised price targets to $26-$28.
Avi Kapoor

PRO
UBS Maintains Buy on Minimed Group, Raises Price Target to $28

UBS analyst Patrick Wood maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $25 to $28.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved